nivolumab + bevacizumab + pemetrexed

This combination therapy consists of **nivolumab** (a PD-1 immune checkpoint inhibitor), **bevacizumab** (a monoclonal antibody targeting vascular endothelial growth factor A/VEGF-A), and **pemetrexed** (an antifolate antineoplastic agent). Each drug has a distinct mechanism and rationale for use in oncology: - **Nivolumab** is a human IgG4 monoclonal antibody that inhibits the programmed death-1 (PD-1) pathway, releasing T-cell mediated antitumor activity[4]. - **Bevacizumab** is a monoclonal antibody that binds VEGF-A, preventing angiogenesis and thereby inhibiting tumor blood supply[2]. - **Pemetrexed** is a small-molecule antineoplastic agent that disrupts folate-dependent metabolic processes essential for cell replication. This combination exploits checkpoint blockade (nivolumab), anti-angiogenesis (bevacizumab), and cytotoxicity (pemetrexed). It is of research interest in malignant pleural mesothelioma, non-squamous non-small cell lung cancer, and potentially other solid tumors. Some clinical trials have evaluated similar combinations, but often with additional agents or with carboplatin or cisplatin substituted for one of the above[2][3][5]. No standard regulatory approval exists for exactly this three-drug combination.